Micro Aftermath Archived

I risultati contrastanti della sperimentazione del retatrutide di LLY

Attività in calo — la narrativa perde rilevanza.

Punteggio
0,3
Velocità
▲ 0,0
Articoli
6
Fonti
2

Cronologia del Sentiment

Cronologia degli Eventi

Apr 05, 2026
Jim Cramer Believes Eli Lilly’s “Weight Loss Pill Will Be a Blockbuster” Bullish
Mar 28, 2026
1 Reason Eli Lilly Stock Is Still a Buy Neutral
Mar 22, 2026
Should You Buy Eli Lilly Stock Before April 10? Bullish
Mar 21, 2026
RBC Capital Sees Eli Lilly’s (LLY) Retatrutide as Key Growth Driver despite … Neutral

Articoli Correlati

Jim Cramer Believes Eli Lilly’s “Weight Loss Pill Will Be a Blockbuster”

Yahoo Finance · Apr 05, 2026
Mixed

Should You Buy Eli Lilly Stock Before April 10?

Nasdaq · Mar 22, 2026
Mixed

Eli Lilly and Company (LLY) Announces Positive Topline Results From the Phase 3 ADorable-1 Trial

Yahoo Finance · Mar 22, 2026
Bearish

RBC Capital Sees Eli Lilly’s (LLY) Retatrutide as Key Growth Driver despite Mixed Trial Results

Yahoo Finance · Mar 21, 2026
Mixed

Cronologia

Prima apparizioneMar 21, 2026
Ultimo aggiornamentoMar 21, 2026